source · application/json
source_29c9d84060bb4776
sha256 ba0e26c59f921ab94cb382ea963a071516aef3eeab990bcbf5bd1bb85f58d03c
by researka:v2 · 2026-06-26 06:30:00.173560+04:00
{"publication_id": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "traces": [{"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Evidence-honesty note: 24/27 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "This paper synthesizes evidence on Everolimus across 27 accepted source papers and 553 high-confidence extracted claims.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 25 adjacent clinical sources, and 2 mechanistic or model-system sources, with no load-bearing cross-study disagreements across the evidence base.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Positive study-level signals are summarized in the mortality and survival outcome class, null signals in the contextual adjacent evidence, skeletal, fracture, and bone, immune and inflammation outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "The conclusion is that Everolimus remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-everolimus-v06-DAILY-2026-06-26T02-23-24Z`.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, mechanism, mortality and survival, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Evidence type metadata note: evidence-type labels are resolved against source excerpts; review, RCT/trial, and excerpt evidence are reclassified under the source classification map before claims are interpreted.", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Source-context verification gap: 5 source-bundle records have no DOI, PMID, PMCID, or trial identifier in the available metadata. They remain traceable source-bundle records, but are distinguished from externally identifier-verified peer-reviewed sources in the source-context map and do not independently upgrade evidence certainty.", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "| Everolimus / Contextual Adjacent Evidence | n=16; claims=353 | significant source statistic in 7/16 sources; receipt-level direction coded null | 9 indirect; 7 review | limited corpus depth in this outcome class |", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "| Everolimus / Skeletal, Fracture, and Bone | n=3; claims=14 | reported statistic in 1/3 sources; receipt-level direction coded null | 3 review | limited corpus depth in this outcome class |", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "| Everolimus / Immune and Inflammation | n=2; claims=38 | significant source statistic in 2/2 sources; receipt-level direction coded null | 1 indirect; 1 review | limited corpus depth in this outcome class |", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "| Everolimus / Dosing and Pharmacokinetics | n=1; claims=79 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 mechanistic | single-source slice; hypothesis-generating |", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Oncology and cancer context: 17 sources; significant source statistic in 8/17 sources; receipt-level direction coded null.", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Dosing and pharmacokinetics context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Transplant and fibrosis context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Contextual Adjacent Evidence remains a separate Results slice for Everolimus (n=16; claims=353; significant source statistic in 7/16 sources; receipt-level direction coded null; 9 indirect; 7 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Dosing and Pharmacokinetics remains a separate Results slice for Everolimus (n=1; claims=79; significant source statistic in 1/1 sources; receipt-level direction coded null; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Several clinically meaningful outcomes in this synthesis are supported by only a single source, which prevents any within-corpus replication. Single-trial outcomes should therefore be treated as hypothesis-generating rather than as replicated findings.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "The enrolled populations are narrow and disease-specific, which constrains external validity. Healthy older adults without malignancy are effectively absent; the closest enrollment is the LB TORC Inhibition 2019 cohort of 652 older adults at increased respiratory-tract-infection risk , which used a related but distinct TORC1 inhibitor (RTB101), not everolimus. Generalizing safety or efficacy to non-oncologic, community-dwelling older adults therefore overreaches what these sources can support.", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "Several clinically relevant claims are supported only by mechanistic or preclinical evidence, which the surrogate-endpoint caution articulated by Ioannidis 2005 explicitly flags as insufficient for hard-outcome inference. Translating these mechanistic signals into human clinical recommendations requires direct endpoint evidence that the curated corpus does not currently supply, and any such translation should be treated as a research priority rather than as a supported inference.", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1186/s40360-025-01079-8", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "url": "https://doi.org/10.1186/s40360-025-01079-8"}, {"doi": "10.3389/fimmu.2021.753412", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "url": "https://doi.org/10.3389/fimmu.2021.753412"}, {"doi": "10.3727/096504022X16418911579334", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "url": "https://doi.org/10.3727/096504022X16418911579334"}, {"doi": "10.3389/fonc.2022.874091", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "url": "https://doi.org/10.3389/fonc.2022.874091"}, {"doi": "10.3389/fmolb.2022.981962", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "url": "https://doi.org/10.3389/fmolb.2022.981962"}], "claim": "The principal limitation is evidence-role imbalance. The retained corpus contains no sources classified primarily as direct clinical evidence, 25 adjacent clinical sources, and 2 mechanistic or model-system sources, which means causal interpretation depends on how much weight is assigned to each evidence tier.", "claim_id": "claim_30"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14",
"researka_submission_id": "128a3efa-aea0-44ed-9ad2-5ded7d3615c6",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/3f0afbf6-e835-4b75-ae70-8dfca79bcb14/sidecars/citation_traces.json"
}